[Recombinant interleukin-2 (roncoleukin) in therapy of the patients with skin melanoma].

Abstract

The article deals with a problem of combined use of interferon (laferon) and interleukin in patients with skin melanoma. Recombinant interleukin-2 (rIL-2) was included into the worked-out scheme. Patients with primary-localized skin melanoma (T(2-4)N0M0) have been studied. Three groups were chosen. 901 patients of the control group underwent excision of tumor (e/t); 34 patients of the first study group (e/1) were given endolymphatic interferontherapy (ift); 35 patients of the second study group were subjected to excision of tumor followed by endolymphatic interferontherapy. One-year relapse-free survival among patients of the control group reached 57.6+/-1.6%, 1st study group--70.5+/-7.8% and 2nd study group--83.6+/-6.7%. Total one-year survival among patients of the control group was 92.1+/-0.9%, in the 1st study group--97.0+/-2.9%, in the 2nd study group--92.7+/-5.0%. Thus, the combined use of recombinant interferon (laferon and interleukin (ronkoleukin) in treatment schemes of malignant skin melanoma was proved to be perspective.

• Authors: S I Korovin, B A Tolstopiatov, O A Dovgopolaia, A Iu Palivets
• Journal: Likars'ka sprava (Lik Sprava) 2005 Jan-Feb Issue 1-2 Pg. 82-6 ISSN: 1019-5297 [Print] Ukraine
• PMID: 15916002 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Interferon Type I
• Interferon-alpha
• Interleukin-2
• Recombinant Proteins
• interferon-alpha 8

Topics

• Adolescent
• Adult
• Aged
• Chemotherapy, Adjuvant
• Disease-Free Survival
• Female
• Humans
• Interferon Type I (administration & dosage, therapeutic use)
• Interferon-alpha
• Interleukin-2 (administration & dosage, therapeutic use)
• Male
• Melanoma (drug therapy, mortality, pathology, surgery)
• Middle Aged
• Neoplasm Invasiveness
• Recombinant Proteins (administration & dosage, therapeutic use)
• Skin Neoplasms (drug therapy, mortality, pathology, surgery)